Non Small Cell Lung Cancer (NSCLC)

Stage I-III, Resectable

Standard Risk

Completely Resected

ALK Mutation

ECOGE4512
Phase III
Crizotinib vs Observation in NSCLC w/ Anaplastic Lymphoma Kinase (ALK) Fusion Protein Tumors
PI: Wakelee ECOG-ACRIN

CTDNA MRD Testing

LUN0115
Adjuvant Durvalumab for Early Stage NSCLC Patients with ctDNA Minimal Residual Disease
PI: Neal Stanford

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu